

APPENDIX

Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study

Krishna P. Reddy, Fatma M. Shebl, Julia H. A. Foote, Guy Harling, Justine A. Scott,
Christopher Panella, Kieran P. Fitzmaurice, Clare Flanagan, Emily P. Hyle, Anne M. Neilan,
Amir M. Mohareb, Linda-Gail Bekker, Richard J. Lessells, Andrea L. Ciaranello, Robin Wood,
Elena Losina, Kenneth A. Freedberg, Pooyan Kazemian, Mark J. Siedner

Contents

S1. Methods: Additional Information	2
Appendix References	9
Table S1	11
Table S2	12
Table S3	13
Table S4	14
Table S5	16
Table S6	17
Table S7	18
Table S8	19
Table S9	20
Table S10	21
Table S11	22
Table S12	23
Table S13	24
Table S14	25
Table S15	26
Table S16	27
Figure S1	28
Figure S2	32
Figure S3	33
Figure S4	34
Figure S5	35
Figure S6	36

METHODS: ADDITIONAL INFORMATION

S1.1. Model Structure and Analytic Overview

Overview

The Clinical and Economic Analysis of COVID Interventions (CEACOV) model consists of several modules that together determine individual health/disease trajectories and epidemic growth. These modules include natural history of disease, transmission, interventions including testing, and resource utilization.

Each model simulation in this analysis started with 1 million individuals. We then used the model to project outcomes over 360 days and extrapolated the results to the KwaZulu-Natal population of 11 million. The incremental cost-effectiveness ratio (ICER) was expressed in terms of undiscounted COVID-19-related healthcare costs during the 360-day model simulation period divided by undiscounted lifetime years-of-life saved (YLS) per COVID-19 death averted during the 360-day model simulation. We also considered YLS when discounted 3%/year (see Section S1.3).

There is much debate around appropriate cost-effectiveness thresholds, especially in low and middle-income countries. In this analysis, we applied an opportunity cost-based threshold for South Africa as reported by Edeka and Stacey.¹ We converted their reported threshold (\$3,015) from 2015 United States dollars (USD) to 2015 South African Rand (ZAR), adjusted for inflation to obtain a value in 2019 ZAR, and subsequently converted from 2019 ZAR to 2019 USD to yield a threshold of \$3,250 per year-of-life saved.^{2,3}

Health States

CEACOV simulates individuals transitioning between the states of susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection with SARS-CoV-2 and COVID-19 disease, recovery from COVID-19, and death. Susceptible individuals face a daily probability of exposure. After being infected with SARS-CoV-2, individuals may progress through the following health states (Figure S2):

- Pre-infectious latency
- Asymptomatic (or presymptomatic) infection
- Mild/moderate disease: symptomatic
- Severe disease: dyspnoea and/or hypoxemia ideally managed in a hospital with standard supplemental oxygen but not requiring intensive care unit (ICU)
- Critical disease: ideally managed in an ICU with high-flow supplemental oxygen, non-invasive positive pressure ventilation, or invasive mechanical ventilation
- Recuperation: only for those recuperating from critical disease and improving while remaining in the hospital or other health care facility
- Recovered

Individuals in the asymptomatic infection, mild/moderate disease, and severe disease states can transition directly to the recovered state. Individuals in the critical disease state can eventually die, or transition to the recuperation state and then to the recovered state. The recovered state is an absorbing state, and recovered individuals are assumed to have full immunity to SARS-CoV-2 over the model time horizon.

Natural History Paths

After being infected with SARS-CoV-2, a susceptible individual first transitions to the pre-infectious latency stage. Then, the individual has an age-dependent probability of progressing along one of four “paths,” culminating in either asymptomatic infection, mild/moderate disease, severe disease, or critical disease. Before reaching a more advanced disease state, individuals must first transition through intermediate states (e.g., those destined for severe disease must first pass through the asymptomatic/presymptomatic infection state and the mild/moderate disease state) (Figure S2).

Transmission

In CEACOV,

$$\text{Effective Transmission Rate (R}_{\text{eff}}) = \text{Nominal Transmission Rate (R}_{\text{nom}}) * \text{Transmission Multiplier}$$

The nominal transmission rate (R_{nom}) is a function of the average number of susceptible persons whom an infected individual contacts per day in a fully susceptible cohort multiplied by the probability of infecting the susceptible person per contact. This nominal transmission rate captures the ratio (not the magnitude) of daily infectivity stratified by disease states in an index epidemic. In other words, it captures the ratio of ‘force of transmission’ across different disease states. Infected individuals do not transmit while they are in the pre-infectious latency state or in the recovered state. Individuals in other infected states can transmit SARS-CoV-2 to susceptible individuals. The effective transmission rate (R_{eff}) changes over time as social interventions alter the number of contacts and infectivity per contact. Thus, the magnitude of the transmission rate is adjusted using the transmission multiplier (see below). In a sense, the effective transmission rate (R_{eff}) in CEACOV is the effective reproductive number (R_e) divided by the average duration of infectivity.

Transmission multipliers are setting-specific, time-dependent adjusting factors. They roughly account for population density and interventions that can alter the number of contacts and infectivity in the setting being modelled.

We assumed that all susceptible persons have an equal probability of contacting infected individuals and acquiring the virus (i.e., homogenous mixing). As the epidemic grows, the number of susceptible persons declines. Thus, not all the daily contacts of infected individuals will be with susceptible persons. The daily infection rate for a susceptible person is equal to the sum of transmission rates from all infected persons across all infection states divided by the cohort size. This leads to an expected daily number of infections equal to the number of susceptible persons multiplied by the infection rate on that day.

Testing and Interventions

In this analysis, testing is performed on a nasopharyngeal specimen by polymerase chain reaction (PCR) assay. We assumed that test characteristics including sensitivity and specificity are independent of disease state – i.e., the sensitivity is the same for those in the mild/moderate disease state and those in the critical disease state. We assumed that, after providing a specimen for testing and while awaiting the test result, hospitalised individuals are isolated and non-hospitalised individuals are advised to self-isolate at home. In the model, test results are acted upon (an intervention is started) on the day that the result is delivered.

S1.2. Model Calibration and Validation

To calibrate our model output with the COVID-19 epidemic in South Africa, we adjusted the transmission multiplier to generate an effective reproduction number (R_e) of 1.5, matching that published by South Africa's National Institute for Communicable Diseases (NICD) based on empirical data collected in the country up to 19 May 2020.⁴ We also evaluated alternative epidemic growth scenarios with $R_e=1.1$, $R_e=1.2$, or $R_e=2.6$, reflecting a range of estimates from different periods and regions in the NICD report.

For validation, we assumed a SARS-CoV-2 infection prevalence of 0.1% at model initiation, corresponding to approximately 11,000 cases among the KwaZulu-Natal population of 11 million people. We then looked to KwaZulu-Natal data to determine the date at which there were 1,100 reported (confirmed) cases of SARS-CoV-2 infection, assuming that the true prevalence was 10 times higher than the reported number of cases. Data compiled by the University of Pretoria indicated that this occurred on 6 May 2020.⁵ This date would thus correspond to "Day 0" in our model. We then compared cumulative deaths through 30 August in the University of Pretoria database with the corresponding Day 116 cumulative deaths in our model. The database indicated 2,100 COVID-19 deaths during that period, while we estimated 2,806 deaths over 116 days in our model with $R_e=1.5$ and the *HT* strategy. Thus, the model output for COVID-19 deaths was similar to the numbers reported in KwaZulu-Natal, considering likely undercounting of COVID-19-related deaths.⁶

S1.3. Input Parameters

Natural History

We calculated age-stratified disease path probabilities. We used the proportions of people with COVID-19 who were: (a) asymptomatic,^{7,8} (b) admitted to the ICU,⁹ (c) hospitalised,⁹ and (d) undiagnosed,¹⁰ and the age-stratified proportions of different disease severity states.¹¹

We used the following sources to derive the duration of time in each state: presymptomatic infectious time;^{11,12} duration of viral shedding based on PCR detectability (WHO-China CDC Report,¹¹ Hu et al.,¹³ Zhou et al.¹⁴); time to development of pneumonia (Wang et al.¹⁵); time to ICU admission (Zhou et al.¹⁴); time spent in the ICU (Zhou et al.¹⁴); and median time to death (Zhou et al.¹⁴). We calculated the transition probabilities until recovery (defined as the end of viral shedding) and the transition probabilities between disease states including death. Subsequently, after determining the duration in each state, we estimated transition rates. We then calculated transition probabilities from the transition rates.

$$\text{Transition rate} = rt = \frac{1}{\text{duration of the transition}}$$

$$\text{Transition probability} = p = 1 - \exp(-rt).$$

Life Expectancy and Years-of-Life Lost

We estimated the years-of-life saved (YLS) from each averted death from COVID-19 in KwaZulu-Natal, South Africa. To do this, we calculated years-of-life lost (YLL), defined as the average number of years a person would have lived had s/he not died from COVID-19.¹⁶ The absolute number of YLL were:^{16,17}

$$YLL_{age\ i} = Deaths_{age\ i} * LE_{age\ i}$$

Where,

Deaths_{age i} is the number of deaths from COVID-19 in the age stratum,

LE_{age i} is the life expectancy in South Africa in the age stratum.

Therefore, age-stratified deaths and age-stratified life expectancy are needed. We obtained or calculated these data from the following sources,

1. Age-stratified distribution of cases: We used the published South Africa National Institute for Communicable Disease for Communicable Diseases (NICD) COVID-19 epidemiology report.¹⁸
2. Age-stratified distribution of deaths: We used data from the South Africa NICD COVID-19 update report.¹⁹
3. Calculate life expectancy: Published South Africa life tables are stratified by sex. Our model analysis was not stratified by sex. Therefore, we generated a standard abridged life table, not stratified by sex.
 - I. To create a life table for South Africa, we used the following data:
 - a. All-cause mortality: World Health Organization disease burden and mortality²⁰
 - b. Age- and sex-stratified population size: United Nations World Population Prospects 2019²¹
 - II. Using SAS software (Cary, North Carolina, USA), we generated a life table. From this, we estimated the expected life-years at any given age.

4. Calculate the age-stratified absolute number of YLL:

$$YLL_{age\ i} = Deaths_{age\ i} * LE_{age\ i}$$

5. Calculate the total absolute number of YLL, base case:

$$YLL_{base\ case} = \sum YLL_{age\ i}$$

6. Calculate the mean YLL:

$$Mean\ YLL = \frac{\sum YLL_{age\ i}}{\sum Deaths_{age\ i}}$$

7. Calculate the absolute number of YLL associated with different intervention strategies: We used the mean YLL to estimate intervention-specific YLL

$$YLL_{intervention\ j} = Mean\ YLL * Deaths_{intervention\ j}$$

The estimates for YLL for each COVID-19 death were 16.8 (undiscounted) and 12.5 (discounted 3%/year).

Transmission

Assuming that (a) R_0 is 2.6 for individuals with asymptomatic and mild/moderate disease, (b) R_0 is one-tenth of 2.6 for individuals with severe and critical disease,²² and (c) viral shedding times are 9.5, 12, 19, and 24 days for individuals with asymptomatic, mild/moderate, severe, and critical disease, respectively,^{11,13,14} we estimated the nominal transmission rate as described above in S1.1.

Resource Utilization and Costs

We applied costs from the health sector perspective. We adjusted costs to 2019 United States dollars, using South Africa-specific inflation and exchange rates.^{2,3} We obtained costs of clinical care from Mahomed et al. and Netcare Hospitals.^{23,24} We obtained the cost of PCR testing, including personnel and supplies, from the Africa Health Research Institute (personal communication). Costs and sources are indicated in Tables S12-S16.

We derived the number of ICU and non-ICU hospital beds available in KwaZulu-Natal (KZN) based on data reported by the South Africa Department of Health:

$$(a)\ ICU\ hospital\ beds_{KZN} = \frac{Total\ (non - ICU\ and\ ICU)\ hospital\ beds_{KZN}}{Total\ (non - ICU\ and\ ICU)\ hospital\ beds_{South\ Africa}} \times ICU\ hospital\ beds_{South\ Africa}$$

$$(b)\ non - ICU\ hospital\ beds_{KZN} = \frac{Total\ (non - ICU\ and\ ICU)\ hospital\ beds_{KZN}}{Total\ (non - ICU\ and\ ICU)\ hospital\ beds_{South\ Africa}} \times non - ICU\ hospital\ beds_{South\ Africa}$$

We derived the costs of additional intervention strategies from data supplied by the Africa Health Research Institute. The daily per-person costs of isolation and quarantine centre beds were based on the cost of a 500-person tent and personnel requirements.

To calculate the per-person cost of contact tracing and mass symptom screening, including personnel, supplies, and transportation, we assumed that community health workers could visit 30 households per day, with 5 individuals per house, on 20 days per month:

$$Per\ person\ contact\ tracing\ cost = \frac{Monthly\ cost\ of\ contact\ tracing}{Days\ per\ month \times Households\ per\ day \times Individuals\ per\ house}$$

(the same per-person cost was applied for mass symptom screening)

We assumed that the per-unit costs of resources would be the same regardless of the total quantity. For example, per-test cost of performing a PCR assay was the same regardless of the number of PCR assays performed, and per-person daily cost of a stay at an isolation centre was the same regardless of the number of individuals housed at an isolation centre.

Costs of the various interventions included expenses associated with personnel, supplies, personal protective equipment, and transportation of specimens and personnel. We did not account for additional costs of staff training. The per-test cost of a PCR assay included the cost of reagents and personnel and specimen transportation, but not

the cost of additional machines or training new technicians. To reflect uncertainty in our estimates, we varied costs between 50% and 200% of their base case value in sensitivity analyses.

Mass Symptom Screening Efficacy

To calculate the increase in the cumulative probability of undergoing testing from mass symptom screening (MS) relative to contact tracing (CT), we assumed that MS would screen the population of 11 million twice per year. We assumed that individuals with mild/moderate symptoms are symptomatic for 10 days, on average:

$$\text{Increase in MS efficacy relative to CT} = \frac{\text{Average duration of mild/moderate symptoms} \times \text{screens per year}}{\text{Time (days)}}$$

$$\text{Increase in MS efficacy relative to CT} = \frac{10 \times 2}{360} = 5.6\%$$

Influenza-like Illness in Mass Symptom Screening

Based on a cross-sectional household survey conducted in KwaZulu-Natal by the Africa Health Research Institute, approximately 1% of individuals have symptoms of an influenza-like illness (ILI).²⁶ To calculate the number of individuals with ILI who would be tested under MS each day:

$$\text{Individuals with ILI tested under MS, daily} = \frac{\text{Individuals screened under MS} \times \text{screens per year}}{\text{Time (days)}} \times \text{prevalence of ILI}$$

$$\text{Individuals with ILI tested under MS, daily} = \frac{11,000,000 \times 2}{360} \times 1\% = 611$$

Tracing of Non-infected Contacts

The number of non-infected individuals who present to care due to contact tracing is linked to the number of positive PCR tests on a given day in our model – the event that initiates a contact trace. The 26 July 2020 COVID-19 KwaZulu-Natal situation report contained the following data related to contact tracing:²⁷

Description	Value
Total cases	64,061
Number of contacts identified, traced, and tested	50,757
Number of contacts testing positive	2,152
Number of contacts testing negative	48,605

We assumed that a PCR test has a sensitivity of 70% and specificity of 100%, which implies that of 50,757 contacts identified, traced, and tested, approximately 3,074 are infected with SARS-CoV-2 and 47,683 are not. We then derived the expected number of non-infected contacts traced per positive PCR result (η_0) by dividing the number of non-infected contacts traced by the number of “original” confirmed cases of COVID-19 in the 26 July 2020 situation report.²⁷

$$\eta_0 = \frac{47,683}{64,061 - 2,152} = 0.77$$

We modified the expected number of non-infected contacts traced per positive PCR result to reflect the prevalence of active disease within the population as follows:

$$\eta(t) = \eta_0 \cdot \frac{S(t) + R(t)}{N_0}$$

where $S(t)$ and $R(t)$ represent the number of susceptible and recovered individuals on day t , and N_0 represents the population of KwaZulu-Natal. The number of non-infected contacts traced on day t is given by

$$N_{CT}(t) = \eta(t) \cdot N_{PCR}^+(t - \theta)$$

where $N_{PCR}^+(t - \theta)$ represents the number of positive PCR tests on day $t - \theta$, where θ represents the number of days it takes to trace an individual's contacts (assumed to be two days). Once traced, non-infected contacts may incur costs related to PCR testing and quarantine centres in the same manner as infected individuals.

APPENDIX REFERENCES

- 1 Edeka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. *Health Policy Plan* 2020; **35**: 546–55.
- 2 Board of Governors of the Federal Reserve System (US). South Africa / U.S. Foreign Exchange Rate. FRED, Federal Reserve Bank of St. Louis. <https://fred.stlouisfed.org/series/DEXSFUS> (accessed Sept 8, 2020).
- 3 Organization for Economic Co-operation and Development. Consumer Price Index: All Items for South Africa. FRED, Federal Reserve Bank of St. Louis. <https://fred.stlouisfed.org/series/ZAFCPIALLMINMEI> (accessed Sept 8, 2020).
- 4 National Institute for Communicable Diseases. The Initial and Daily COVID-19 Effective Reproductive Number (R) in South Africa. 2020; published online May 27. <https://www.nicd.ac.za/wp-content/uploads/2020/05/The-Initial-and-Daily-COVID-19-Effective-Reproductive-Number-R-in-South-Africa-002.pdf> (accessed June 9, 2020).
- 5 Data Science for Social Impact Research Group @ University of Pretoria. Coronavirus COVID-19 (2019-nCoV) Data Repository and Dashboard for South Africa. 2020; published online Sept 8. <https://github.com/dsfsi/covid19za> (accessed Sept 8, 2020).
- 6 South African Medical Research Council. Report on Weekly Deaths in South Africa. South African Medical Research Council. 2020; published online Aug 26. <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa> (accessed Sept 8, 2020).
- 7 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* 2020; **25**. DOI:10.2807/1560-7917.ES.2020.25.10.2000180.
- 8 Tao Y, Cheng P, Chen W, *et al*. High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China. *Emergency Medicine*, 2020 DOI:10.1101/2020.03.16.20037259.
- 9 Massachusetts Department of Health. COVID-19 Dashboard. 2020. <https://www.mass.gov/doc/covid-19-dashboard-april-20-2020/download> (accessed June 10, 2020).
- 10 Rothwell J. Estimating COVID-19 Prevalence in Symptomatic Americans. 2020; published online April 3. <https://news.gallup.com/opinion/gallup/306458/estimating-covid-prevalence-symptomatic-americans.aspx> (accessed June 10, 2020).
- 11 WHO-China Joint Mission on Coronavirus Diseases 2019 (COVID-19). Report of the WHO-China Joint Mission on Coronavirus Diseases 2019 (COVID-19). 2020. <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> (accessed May 27, 2020).
- 12 He X, Lau EHY, Wu P, *et al*. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020; **26**: 672–5.
- 13 Hu Z, Song C, Xu C, *et al*. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci* 2020; **63**: 706–11.
- 14 Zhou F, Yu T, Du R, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
- 15 Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061.

- 16 Gardner JW, Sanborn JS. Years of potential life lost (YPLL)--what does it measure? *Epidemiology* 1990; **1**: 322–9.
- 17 Martinez R, Soliz P, Caixeta R, Ordunez P. Reflection on modern methods: years of life lost due to premature mortality-a versatile and comprehensive measure for monitoring non-communicable disease mortality. *Int J Epidemiol* 2019; **48**: 1367–76.
- 18 National Institute for Communicable Diseases, South Africa. COVID-19 Weekly Epidemiology Brief. <https://www.nicd.ac.za/wp-content/uploads/2020/05/Week-18-Weekly-Epidemiology-Brief-Template-V8.pdf> (accessed Sept 3, 2020).
- 19 National Institute for Communicable Diseases, South Africa. COVID-19 Update. NICD. 2020; published online May 2. <https://www.nicd.ac.za/covid-19-update-46/> (accessed Sept 3, 2020).
- 20 World Health Organization. Disease Burden and Mortality Estimates: Cause-Specific Mortality, 2000-2016. 2017. <https://www.nicd.ac.za/covid-19-update-36/> (accessed June 10, 2020).
- 21 United Nations. World Population Prospects, South Africa. 2019. <https://population.un.org/wpp/Download/Standard/Population/> (accessed June 10, 2020).
- 22 Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med* 2020; **27**. DOI:10.1093/jtm/taaa021.
- 23 Mahomed S, Mahomed OH. Cost of intensive care services at a central hospital in South Africa. *S Afr Med J* 2018; **109**: 35.
- 24 Netcare Hospitals. Netcare Tariffs. 2016. <https://www.netcarehospitals.co.za/> (accessed June 10, 2020).
- 25 National Department of Health, South Africa. COVID-19 Public Health Response. 2020; published online April 10. <https://sacoronavirus.co.za/2020/04/11/covid-19-public-health-response/> (accessed June 10, 2020).
- 26 Siedner MJ, Harling G, Derache A, *et al*. Protocol: Leveraging a demographic and health surveillance system for Covid-19 Surveillance in rural KwaZulu-Natal. *Wellcome Open Res* 2020; **5**: 109.
- 27 Ponch Bapela M, Mhlongo B, editors. KwaZulu-Natal Department of Health COVID-19 Situational Report: 26 July 2020. .
- 28 World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). <http://www.who.int/choice/en/> (accessed April 28, 2020).
- 29 Reddy KP, Gupta-Wright A, Fielding KL, *et al*. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. *Lancet Glob Health* 2019; **7**: e200–8.
- 30 Craig J, Kalanxhi E, Hauck S. National estimates of critical care capacity in 54 African countries. *Public and Global Health*, 2020 DOI:10.1101/2020.05.13.20100727.

Table S1. Additional natural history input parameters for a model-based analysis of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

Parameter	Value				Source
Disease path probability*, stratified by age, %	Asymp.	Mild/Mod.	Severe	Critical	†
0-19y	29.93	69.78	0.25	0.03	
20-59y	17.90	80.38	0.80	0.93	
≥60y	17.10	76.37	1.40	5.16	
Duration of health states, stratified by disease path, days	Asymp.	Mild/Mod.	Severe	Critical	†
Pre-infectious latency	2.6	2.6	2.6	2.6	
Asymptomatic	9.5	2.0	2.0	2.0	
Mild/moderate disease	--	10.0	6.5	3.0	
Severe disease	--	--	10.5	7.1	
Critical disease	--	--	--	11.9	
Recuperation after critical disease	--	--	--	5.7	
Mortality probability among those with critical COVID-19 disease, stratified by age, daily, %	0-19y	20-59y	≥60y		†
Without hospital care	11.7500	16.6200	20.3300		
With hospital care	0.0006	0.3800	5.0000		

COVID-19: coronavirus disease 2019. y: years. Asymp.: asymptomatic. Mod.: moderate.

*Disease path probability refers to the likelihood that an individual, once infected with SARS-CoV-2, will eventually progress to the specified COVID-19 disease state.

†Derivation of natural history parameters is described in the appendix, p.5.

Table S2. Intervention-related input parameters for a model-based analysis of COVID-19 intervention strategies in KwaZulu-Natal, South Africa.

Intervention Strategies	HT	HT+CT	HT+CT +IC	HT+CT +IC+MS	HT+CT +IC+QC	HT+CT +IC+MS+QC	Source
Cumulative probability of undergoing testing, over health state duration, %							
Susceptible	0	Variable	Variable	Variable	Variable	Variable	*
Pre-infectious latency	0	10 (5-20)	10 (5-20)	12.5 (6.25-25)	10 (5-20)	12.5 (6.25-25)	Asm.
Asymptomatic	0	10 (5-20)	10 (5-20)	12.5 (6.25-25)	10 (5-20)	12.5 (6.25-25)	Asm.
Mild/moderate disease	30	35 (33-40)	35 (33-40)	40 (35-50)	35 (33-40)	40 (35-50)	Asm.
Severe disease	100	100	100	100	100	100	Asm.
Critical disease	100	100	100	100	100	100	Asm.
Recovered	0	Variable	Variable	Variable	Variable	Variable	*
Reduction in onward transmission, % (range)							
Home isolation/quarantine	50 (25-75)	50 (25-75)	50 (25-75)	50 (25-75)	--	--	Asm.
Isolation centre	--	--	95 (75-99)	95 (75-99)	95 (75-99)	95 (75-99)	Asm.
Quarantine centre	--	--	--	--	95 (75-99)	95 (75-99)	Asm.

COVID-19: coronavirus disease 2019. Asm.: assumption. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Values indicated are those applied in the base case analyses or, in parentheses, the ranges evaluated in sensitivity analysis.

*Testing among those in the susceptible or recovered states is described in the appendix, p.7-8.

Table S3. Sensitivity analysis: varying the costs of contact tracing and mass symptom screen strategies.

Cost	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
Contact tracing and mass symptom screening cost changed to 50% of base case value	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	551,000,000	270
	<i>HT+CT</i>	322,970	584,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	637,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	778,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	963,000,000	DOMINATED
Contact tracing and mass symptom screening cost changed to 200% of base case value	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	322,970	596,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	27,220	640,000,000	480
	<i>HT+CT+IC+MS</i>	60,930	729,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	786,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	970,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, contact tracing and mass symptom screening cost \$3/person.

Table S4. Sensitivity analysis: varying the cost of hospitalisation.

Cost	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
Hospital (non-ICU) bed daily cost changed to WHO estimate (\$56/day)*	<i>HT</i>	450,940	381,000,000	--
	<i>HT+CT</i>	322,970	535,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	27,220	568,000,000	440
	<i>HT+CT+IC+MS</i>	60,930	641,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	743,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	938,000,000	DOMINATED
Hospital (non-ICU) bed daily cost changed to 50% of base case value	<i>HT</i>	450,940	395,000,000	--
	<i>HT+CT</i>	322,970	548,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	27,220	571,000,000	420
	<i>HT+CT+IC+MS</i>	60,930	647,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	752,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	945,000,000	DOMINATED
Hospital (non-ICU) bed daily cost changed to 200% of base case value	<i>HT</i>	450,940	521,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	600,000,000	190
	<i>HT+CT</i>	322,970	669,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	709,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	837,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	1,007,000,000	DOMINATED
ICU bed daily cost changed to 50% of base case value	<i>HT</i>	450,940	281,000,000	--
	<i>HT+CT</i>	322,970	419,000,000	dominated
	<i>HT+CT+IC+QC+MS</i>	27,220	521,000,000	570
	<i>HT+CT+IC+MS</i>	60,930	541,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	609,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	831,000,000	DOMINATED
ICU bed daily cost changed to 200% of base case value	<i>HT+CT+IC+MS+QC</i>	27,220	700,000,000	--
	<i>HT</i>	450,940	748,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	922,000,000	DOMINATED
	<i>HT+CT</i>	322,970	927,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	1,124,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	1,234,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, hospital beds cost \$165/person/day and ICU beds cost \$2,048/person/day.

*This cost is based on a WHO-CHOICE estimate.^{28,29}

Table S5. Sensitivity analysis: varying PCR testing parameters.

PCR testing parameter	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
PCR sensitivity changed to 50%	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	322,970	581,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	31,850	583,000,000	350
	<i>HT+CT+IC+MS</i>	78,520	672,000,000	DOMINATED
	<i>HT+CT+IC</i>	152,040	717,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	57,590	870,000,000	DOMINATED
PCR sensitivity changed to 90%	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	322,970	596,000,000	dominated
	<i>HT+CT+IC+MS</i>	51,110	613,000,000	440
	<i>HT+CT+IC+MS+QC</i>	28,150	651,000,000	1660
	<i>HT+CT+IC</i>	92,410	810,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,000	956,000,000	DOMINATED
PCR result return time changed to 1 day	<i>HT</i>	563,720	495,000,000	--
	<i>HT+CT</i>	390,750	639,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	23,520	653,000,000	290
	<i>HT+CT+IC+MS</i>	102,970	963,000,000	DOMINATED
	<i>HT+CT+IC</i>	206,300	995,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	56,850	1,146,000,000	DOMINATED
PCR result return time changed to 7 days	<i>HT</i>	401,500	405,000,000	--
	<i>HT+CT+IC+MS</i>	65,190	537,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	29,440	541,000,000	370
	<i>HT+CT</i>	296,860	569,000,000	DOMINATED
	<i>HT+CT+IC</i>	118,520	691,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	70,000	874,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. PCR: polymerase chain reaction. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, the PCR test has a 70% sensitivity and a 5-day result return time.

Table S6. Sensitivity analysis: varying the cost of the PCR test.

Cost	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
PCR test cost changed to 50% of base case value	<i>HT</i>	450,940	416,000,000	--
	<i>HT+CT</i>	322,970	508,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	27,220	528,000,000	260
	<i>HT+CT+IC+MS</i>	60,930	605,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	714,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	905,000,000	DOMINATED
PCR test cost changed to 200% of base case value	<i>HT</i>	450,940	478,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	686,000,000	490
	<i>HT+CT</i>	322,970	748,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	793,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	912,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	1,086,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. PCR: polymerase chain reaction. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, the PCR test cost \$26/test.

Table S7. Sensitivity analysis: varying the availability of hospital beds and ICU beds.

Number of hospital and ICU beds	Strategy	Peak daily resource use, n			Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
		Hospital (non-ICU) beds	ICU beds				
Base case	<i>HT</i>	4,686	748	450,940	437,000,000	--	
	<i>HT+CT+IC+MS+QC</i>	638	341	27,220	581,000,000	340	
	<i>HT+CT</i>	3,443	748	322,970	588,000,000	DOMINATED	
	<i>HT+CT+IC+MS</i>	1,320	715	60,930	668,000,000	DOMINATED	
	<i>HT+CT+IC</i>	1,925	748	128,890	780,000,000	DOMINATED	
	<i>HT+CT+IC+QC</i>	1,375	737	60,190	965,000,000	DOMINATED	
Number of hospital and ICU beds reduced *	<i>HT</i>	4,466	374	564,280	308,000,000	--	
	<i>HT+CT</i>	3,190	374	438,160	447,000,000	dominated	
	<i>HT+CT+IC+MS+QC</i>	638	341	27,220	581,000,000	510	
	<i>HT+CT+IC+MS</i>	1,210	374	115,000	600,000,000	DOMINATED	
	<i>HT+CT+IC</i>	1,782	374	235,380	646,000,000	DOMINATED	
	<i>HT+CT+IC+QC</i>	1,199	374	120,740	904,000,000	DOMINATED	

ICU: intensive care unit. USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, the numbers of available hospital (non-ICU) beds and ICU beds are 26,220 and 748 per 11 million people, respectively.

*We changed the available number of hospital (non-ICU) and ICU beds to match the reported median numbers across countries in sub-Saharan Africa: 22,275 and 374 per 11 million people, respectively.

Table S8. Sensitivity analysis: varying the effective reproductive number.

Effective reproduction number (R_e)	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
1.1	<i>HT+CT+IC+QC</i>	2,590	110,000,000	--
	<i>HT+CT+IC</i>	3,700	114,000,000	DOMINATED
	<i>HT+CT</i>	8,330	127,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	2,040	167,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	1,300	171,000,000	47,410
	<i>HT</i>	37,960	182,000,000	DOMINATED
1.2	<i>HT+CT+IC+QC</i>	3,890	139,000,000	--
	<i>HT+CT+IC</i>	6,850	141,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	4,260	183,000,000	DOMINATED
	<i>HT+CT+IC+QC+MS</i>	2,040	190,000,000	27,590
	<i>HT+CT</i>	32,040	276,000,000	DOMINATED
	<i>HT</i>	97,600	393,000,000	DOMINATED
1.5	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
2.6	<i>HT</i>	933,730	353,000,000	--
	<i>HT+CT</i>	890,210	532,000,000	4,130
	<i>HT+CT+IC</i>	838,360	1,170,000,000	dominated
	<i>HT+CT+IC+MS</i>	811,510	1,317,000,000	9,970
	<i>HT+CT+IC+QC</i>	795,580	2,380,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	758,910	2,634,000,000	25,040

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

Table S9. Sensitivity analysis: varying the efficacies of contact tracing and mass symptom screening.

Efficacies of contact tracing and mass symptom screening for case detection	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Changed to 50% of base case value (less efficacious)	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	393,350	582,000,000	dominated
	<i>HT+CT+IC</i>	269,080	849,000,000	dominated
	<i>HT+CT+IC+MS</i>	220,560	893,000,000	1,980
	<i>HT+CT+IC+QC</i>	215,930	1,343,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	143,520	1,350,000,000	5,930
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
Changed to 200% of base case value (more efficacious)	<i>HT+CT+IC+QC</i>	6,110	164,000,000	--
	<i>HT+CT+IC+MS+QC</i>	2,220	183,000,000	4,810
	<i>HT+CT+IC+MS</i>	6,110	197,000,000	DOMINATED
	<i>HT+CT+IC</i>	20,190	282,000,000	DOMINATED
	<i>HT</i>	450,940	437,000,000	DOMINATED
	<i>HT+CT</i>	196,860	608,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

Table S10. Sensitivity analysis: varying the efficacies of isolation and quarantine centres.

Efficacies of isolation and quarantine centres in transmission reduction, %	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
75 (less efficacious)	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	322,970	588,000,000	1,180
	<i>HT+CT+IC</i>	217,970	894,000,000	dominated
	<i>HT+CT+IC+MS</i>	144,630	909,000,000	1,800
	<i>HT+CT+IC+MS+QC</i>	107,230	1,376,000,000	12,490
	<i>HT+CT+IC+QC</i>	192,410	1,493,000,000	DOMINATED
95 (base case)	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
99 (more efficacious)	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	19,440	437,000,000	1
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	51,300	614,000,000	DOMINATED
	<i>HT+CT+IC</i>	115,190	751,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	49,630	803,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

Table S11. Sensitivity analysis: varying the cost of isolation and quarantine centres.

Cost of isolation and quarantine centres	Strategy	Total life-years lost, n	Total health care costs over 360 days, 2019 USD	ICER, 2019 USD/YLS
Base case	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	581,000,000	340
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	668,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	780,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	965,000,000	DOMINATED
Isolation centre and quarantine centre costs changed to 25% of base case values	<i>HT+CT+IC+MS+QC</i>	27,220	373,000,000	--
	<i>HT</i>	450,940	437,000,000	DOMINATED
	<i>HT+CT+IC+MS</i>	60,930	528,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	568,000,000	DOMINATED
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	598,000,000	DOMINATED
Isolation centre and quarantine centre costs changed to 50% of base case values	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT+IC+MS+QC</i>	27,220	442,000,000	10
	<i>HT+CT+IC+MS</i>	60,930	575,000,000	DOMINATED
	<i>HT+CT</i>	322,970	588,000,000	DOMINATED
	<i>HT+CT+IC</i>	128,890	659,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	700,000,000	DOMINATED
Isolation centre and quarantine centre costs changed to 200% of base case values	<i>HT</i>	450,940	437,000,000	--
	<i>HT+CT</i>	322,970	588,000,000	dominated
	<i>HT+CT+IC+MS</i>	60,930	854,000,000	dominated
	<i>HT+CT+IC+MS+QC</i>	27,220	858,000,000	990
	<i>HT+CT+IC</i>	128,890	1,023,000,000	DOMINATED
	<i>HT+CT+IC+QC</i>	60,190	1,495,000,000	DOMINATED

USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. DOMINATED: strong dominance, resulting in more life-years lost and higher costs than an alternative strategy. dominated: extended dominance, resulting in an ICER higher than that of an alternative strategy that results in fewer life-years lost.

The ICER is the difference between two strategies in discounted costs divided by the difference in life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs.

Strategies are listed in order of ascending costs, per convention of cost-effectiveness analysis.

In the base case, isolation centres cost \$44/person/day and quarantine centres cost \$37/person/day.

Table S12. Cost of supplies for isolation centres and quarantine centres.

Item	Cost, USD*	Quantity	Sub-total, per month, USD	Vendor information
Tent assembly and rental	41,052.63	1	6,842.11 [†]	David Pam Jang Traders, Durban, KZN
Food (3 precooked meals)	12.00	15,000	180,000.00	Functionfoods, Richards Bay, KZN
Computers	1,373.68	20	4,578.95 [†]	First Technology, Umhlanga, KZN
Monitors	263.16	40	1,754.39 [†]	First Technology, Umhlanga, KZN
Wireless router	31.53	10	52.54 [†]	Makro, Springfield, KZN
Portable LED light	11.53	100	192.11 [†]	Makro, Springfield, KZN
Bed	172.50	500	14,375.00 [†]	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Mattress	43.58	500	3,631.58 [†]	Surgical and General Supplies, Durban, KZN
Bedding	12.11	500	1,008.77 [†]	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Cots	68.70	100	1,144.96 [†]	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Biohazardous waste bin	10.00	100	166.69 [†]	Compass Medical Waste Services, Westville, KZN
Biohazardous waste bags	0.35	100	5.91 [†]	Compass Medical Waste Services, Westville, KZN
Refrigerator	807.84	10	1,346.40 [†]	Makro, Springfield, KZN
Privacy screens	106.41	500	8,867.61 [†]	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
File cabinet	142.05	100	2,367.54 [†]	Makro, Springfield, KZN
Computer desk	52.58	50	438.16 [†]	Makro, Springfield, KZN
Whiteboard	47.32	20	157.72 [†]	Makro, Springfield, KZN
Lock box	133.76	50	1,114.69 [†]	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Tape dispenser	2.88	100	288.42	Makro, Springfield, KZN
Tape	1.04	100	104.21	Makro, Springfield, KZN
General waste bin	5.53	100	552.63	Makro, Springfield, KZN
General waste bags	2.47	100	247.11	Makro, Springfield, KZN
Cleaning products	5.66	100	566.11	Makro, Springfield, KZN
Fire extinguisher	29.96	50	1,498.03	Fire Check, Durban, KZN
Laundry service	1.23	500	616.46	Kingsdale Steam Laundry CC, Durban, KZN
Portable toilet	18.16	100	1,815.79	Sanitech, Durban, KZN
Wheelchair accessible toilet	92.61	20	1,852.11	Sanitech, Durban, KZN
Portable toilet (services)	21.18	120	2,542.11	Sanitech, Durban, KZN
Gloves	0.05	90,000	4,902.63	Lasec SA (PTY) LTD, Westville, KZN
Disposable gowns	1.97	45,000	88,519.74	Surgical and General Supplies, Durban, KZN
Face shields	1.73	45,000	77,636.84	Surgical and General Supplies, Durban, KZN
Face masks	0.79	75,000	59,013.16	Surgical and General Supplies, Durban, KZN
Microwave oven	63.11	10	631.05	Makro, Springfield, KZN
Disposable cups	1.52	900	1,371.32	Makro, Springfield, KZN
Disposable plates	2.10	900	1,892.37	Makro, Springfield, KZN
Portable sink	42.37	500	21,184.21	Sanitech, Durban, KZN
Portable sink (services)	18.16	120	2,178.95	Sanitech, Durban, KZN
Biohazard spill kit	47.82	100	4,781.58	SpillTech, Congella, KZN
Infrared thermometer	111.97	100	11,197.37	Surgical and General Supplies, Durban, KZN
Stethoscopes	2.42	500	1,210.53	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Toilet and sink deliveries	120.21	10	1,202.05	Sanitech, Durban, KZN

USD: United States dollars. KZN: KwaZulu-Natal, South Africa. GP: Gauteng, South Africa.

*Cost estimates were obtained in May 2020.

[†]Cost amortized over six months.

Table S13. Cost of supplies for contact tracing.

Item	Cost, USD*	Quantity	Sub-total, per month, USD	Vendor information
Infrared thermometer	111.97	2	223.95	Surgical and General Supplies, Durban, KZN
Stethoscopes	2.42	2	4.48	Kendon Medical Supplies (PTY) LTD, Johannesburg, GP
Gloves	0.05	200	10.89	Lasec SA (PTY) LTD, Westville, KZN
Disposable gowns	1.97	600	1,180.26	Surgical and General Supplies, Durban, KZN
Face shields	1.73	600	1,035.16	Surgical and General Supplies, Durban, KZN
Face masks	0.79	600	472.11	Surgical and General Supplies, Durban, KZN

USD: United States dollars. KZN: KwaZulu-Natal, South Africa. GP: Gauteng, South Africa.

*Cost estimates were obtained in May 2020.

Table S14. Personnel costs.

Category	Monthly salary, USD*	Quantity	Sub-total, per month, USD	Source
Isolation centres				
Nurse (junior professional)	1,494.84	40	59,793.68	Median AHRI position payscale
Nurse (senior professional)	2,111.21	8	16,889.68	Median AHRI position payscale
Nursing assistant	916.79	40	36,671.58	Median AHRI position payscale
Janitorial staff (3 days per week)	697.26	10	6,972.63	Median AHRI position payscale
Project manager	2,661.41	1	2,661.41	Median AHRI position payscale
Unarmed security guard	1200.51	10	12,005.05	Republic Watch Security, Mtubatuba, KZN
Quarantine centres				
Nurse (junior professional)	1,494.84	5	7,474.21	Median AHRI position payscale
Nurse (senior professional)	2,111.21	2	4,222.42	Median AHRI position payscale
Nursing assistant	916.79	10	9,167.89	Median AHRI position payscale
Janitorial staff (3 days per week)	697.26	5	3,486.32	Median AHRI position payscale
Project manager	2,661.41	1	2,661.41	Median AHRI position payscale
Unarmed security guard	1200.51	10	12,005.05	Republic Watch Security, Mtubatuba, KZN
Contact tracing and mass screening				
Nurse (junior professional)	1,494.84	2	2,989.68	Median AHRI position payscale

USD: United States dollars. KZN: KwaZulu-Natal, South Africa. AHRI: Africa Health Research Institute

*Cost estimates were obtained in May 2020.

Table S15. Transportation costs.

Category	Descriptor / Unit	Value, USD*	Quantity	Sub-total, per month, USD	Source
Isolation centres					
Transport for 99 staff members	Cost per kilometre	26.05	200	5,210.53	AHRI commercial quote
Quarantine centres					
Transport for 23 staff members	Cost per kilometre	6.05	200	1,210.53	AHRI commercial quote
Contact tracing and mass screening					
Transport for 2 staff members	Cost per kilometre	0.26	6000	1,578.95	AHRI commercial quote
Cost of leasing additional vehicle	Cost per month	435.22	1	435.22	AHRI commercial quote

USD: United States dollars. AHRI: Africa Health Research Institute

*Cost estimates were obtained in May 2020.

Table S16. Per-patient costs of testing and interventions.


Category	Daily cost per patient, USD				Source
	Supplies	Personnel	Transportation	Total	
Isolation centres	34.26	9.00	0.35	43.60	*
Quarantine centres	34.26	2.60	0.08	36.94	*
Contact tracing and mass screening	0.98	1.00	0.67	2.64	†
Hospital care (non-ICU)	73.70	91.70	--	165.40	Netcare Hospitals ²⁴
ICU care	875.00	1,089.00	--	1,964.00	Mahomed et al. ²³
Ventilator, mechanical	93.60	--	--	93.60	Netcare Hospitals ²⁴
PCR testing	26.40	0.50	--	26.90	AHRI communication

USD: United States dollars. ICU: intensive care unit. PCR: polymerase chain reaction. AHRI: Africa Health Research Institute.

*The per-patient costs of isolation and quarantine centres were estimated based on the total monthly expenses of an alternate care site with the capacity to treat 500 patients daily, for 30 days per month. The total costs included personnel, fixed costs to establish the centres, supplies, and transportation. We assumed that fixed costs were amortized over 6 months (tables S12-S15).


†The per-instance costs of contact tracing and symptom screening were calculated based on the total monthly expenses and screening capacity of a community health worker team (tables S13-S15). We estimated that a two-person team working 20 days per month could conduct approximately 3000 screens per month, visiting an average of 30 five-person households per day.

Figure S1. Model flowcharts of select COVID-19 epidemic control strategies in KwaZulu-Natal, South Africa.



After providing a specimen for testing and while awaiting the result, hospitalised individuals are isolated and non-hospitalised individuals are advised to self-isolate at home. Test results are acted upon (an intervention is started) on the day the result is delivered.


Figure S1 continued. Model flowcharts of select COVID-19 epidemic control strategies in KwaZulu-Natal, South Africa.



“Contacts” can be symptomatic or asymptomatic. After providing a specimen for testing and while awaiting the result, hospitalised individuals are isolated and non-hospitalised individuals are advised to self-isolate at home. Test results are acted upon (an intervention is started) on the day the result is delivered.

Figure S1 continued. Model flowcharts of select COVID-19 epidemic control strategies in KwaZulu-Natal, South Africa.


(C) Contact Tracing + Isolation Center



“Contacts” can be symptomatic or asymptomatic. After providing a specimen for testing and while awaiting the result, hospitalised individuals are isolated and non-hospitalised individuals are advised to self-isolate at home. Test results are acted upon (an intervention is started) on the day the result is delivered.


Figure S1 continued. Model flowcharts of select COVID-19 epidemic control strategies in KwaZulu-Natal, South Africa.

(D) Contact Tracing + Isolation Center + Quarantine Center




“Contacts” can be symptomatic or asymptomatic. After providing a specimen for testing and while awaiting the result, hospitalised individuals are isolated and non-hospitalised individuals are advised to self-isolate at home. Test results are acted upon (an intervention is started) on the day the result is delivered.

Figure S2. Illustration of health states and disease paths in the CEACOV model.



CEACOV: Clinical and Economic Analysis of COVID Interventions. Mod.: moderate.


Figure S3. Model-projected cumulative and daily SARS-CoV-2 infections by intervention strategy in KwaZulu-Natal, South Africa.



SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. R_e : effective reproduction number. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Panels A and B show model results with $R_e=1.5$. Panels C and D show model results with $R_e=1.2$. Panels A and C depict cumulative SARS-CoV-2 infections (both detected and undetected) over time by intervention strategy. Panels B and D depict daily SARS-CoV-2 infections. In each panel, time 0 on the horizontal axis represents the start of model simulation, with SARS-CoV-2 infection prevalence of 0.1% (~11,000 individuals with SARS-CoV-2 infection in KwaZulu-Natal, South Africa).


Figure S4. Model-projected cumulative and daily COVID-19 deaths by intervention strategy in KwaZulu-Natal, South Africa.



COVID-19: coronavirus diseases 2019. R_e : effective reproduction number. HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre.

Panels A and B show model results with $R_e=1.5$. Panels C and D show model results with $R_e=1.2$. Panels A and C depict cumulative COVID-19 deaths over time by intervention strategy. Panels B and D depict 7-day averages of daily deaths due to COVID-19. In each panel, time 0 on the horizontal axis represents the start of model simulation, with SARS-CoV-2 infection prevalence of 0.1% (~11,000 individuals with SARS-CoV-2 infection in KwaZulu-Natal, South Africa).


Figure S5. Multi-way sensitivity analysis demonstrating cost-effectiveness of strategies across a range of assumptions about the efficacies and costs of key public health interventions.



HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. QC: quarantine centre. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved.

The figure shows results of a multi-way sensitivity analysis in which we varied CT/MS efficacy in detecting COVID-19 cases, IC/QC efficacy in reducing transmission, and IC/QC costs. The color coding indicates the strategy that provided the greatest clinical benefit (YLS) while having an ICER that was below the cost-effectiveness threshold of \$3,250/YLS.¹ In the base case, isolation centres and quarantine centres reduce transmission by 95%; isolation centre care costs \$43·60/person/day and quarantine centre care costs \$36·90/person/day. The effective reproduction number in this analysis was 1·5.

Figure S6. Multi-way sensitivity analysis demonstrating cost-effectiveness of strategies across a range of assumptions about the efficacies and costs of key public health interventions, excluding quarantine centres as an option.



HT: healthcare testing. CT: contact tracing within households. IC: isolation centre. MS: mass symptom screen. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved.

The figure shows results of a multi-way sensitivity analysis in which we varied CT/MS efficacy in detecting COVID-19 cases, IC/QC efficacy in reducing transmission, and IC/QC costs. The color coding indicates the strategy that provided the greatest clinical benefit (YLS) while having an ICER that was below the cost-effectiveness threshold of \$3,250/YLS.¹ In the base case, isolation centres and quarantine centres reduce transmission by 95%; isolation centre care costs \$43·60/person/day and quarantine centre care costs \$36·90/person/day. The effective reproduction number in this analysis was 1·5.